Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs



Rating:

Share or cite this content

Citations should be made in the following way:
S. Siddiqui (Leicester, United Kingdom), M. Bozik (Pittsburgh, United States of America), D. Archibald (Pittsburgh, United States of America), S. Dworetzky (Pittsburgh, United States of America), J. Mather (Pittsburgh, United States of America), R. Killingsworth (Pittsburgh, United States of America), S. Ochkur (Scottsdale, United States of America), E. Jacobsen (Scottsdale, United States of America), R. Panettieri (New Brunswick, United States of America), C. Prussin (Pittsburgh, United States of America). Late Breaking Abstract - Phase 2 trial evaluating the effects of dexpramipexole on blood eosinophils, lung function, and airway biomarkers in eosinophilic asthma. 2900

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma. Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Late Breaking Abstract - Anti-IL-5 mepolizumab minimally influences residual blood eosinophils in severe asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Late Breaking Abstract - Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Late Breaking Abstract - Benralizumab treatment strongly reduces blood basophils in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Exacerbations in the subpopulations and intermediate outcome measures in COPD study (SPIROMICS, NHLBI) are associated with sputum eosinophilia but not blood eosinophilia Source: International Congress 2016 – What's new in biomarker analysis? Year: 2016 Peripheral blood eosinophilia predicts lower airway eosinophilia in asthma and COPD Source: International Congress 2015 – Systemic and airway biomarkers Year: 2015 Distribution of sputum cellular phenotype in a large asthma cohort. Predicting factors for eosinophilic vs neutrophilic inflammation Source: Annual Congress 2013 –Asthma and COPD: diseases with different phenotypes Year: 2013 Late Breaking Abstract - Clinical characteristics and lung function trends of severe eosinophilic asthma patients unresponsive to Mepolizumab Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Pharmacodynamic effect of benralizumab on blood basophils and serum biomarkers in adults with COPD with sputum eosinophilia Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Late Breaking Abstract - Effect of timapiprant, a DP2 antagonist, on airway inflammation in severe eosinophilic asthma Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma Year: 2019 Th2 related biomarkers as predictors of airway eosinophilia in optimally treated smoking asthmatics: An observational study. Source: International Congress 2017 – Techniques in biomarker selection Year: 2017 Late Breaking Abstract - An assessment of potential predictive biomarkers for the treatment of severe eosinophilic asthma with CRTH2 antagonists Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Late Breaking Abstract - A GATA3-specific DNAzyme attenuates sputum eosinophilia in COPD patients with eosinophilic airway inflammation Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017 Airway eosinophilia is not related to clinical and functional findings in a large group of severe refractory asthmatics Source: Annual Congress 2006 - Monitoring airway inflammation – exhaled markers vs induced sputum Year: 2006 Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial Source: Eur Respir J 2007; 30: 457-466 Year: 2007 Can blood eosinophils predict sputum eosinophils in stable COPD? Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease Year: 2015 Late Breaking Abstract - The blood eosinophils count as a predictor of the response for omalizumab (OMA) in patients suffering from severe allergic asthma Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019